GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biotage AB (OTCPK:BITGF) » Definitions » Liabilities-to-Assets

Biotage AB (Biotage AB) Liabilities-to-Assets : 0.24 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Biotage AB Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Biotage AB's Total Liabilities for the quarter that ended in Mar. 2024 was $120.8 Mil. Biotage AB's Total Assets for the quarter that ended in Mar. 2024 was $494.4 Mil. Therefore, Biotage AB's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 was 0.24.


Biotage AB Liabilities-to-Assets Historical Data

The historical data trend for Biotage AB's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotage AB Liabilities-to-Assets Chart

Biotage AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 0.31 0.31 0.30 0.26

Biotage AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 0.25 0.26 0.26 0.24

Competitive Comparison of Biotage AB's Liabilities-to-Assets

For the Medical Instruments & Supplies subindustry, Biotage AB's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotage AB's Liabilities-to-Assets Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biotage AB's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Biotage AB's Liabilities-to-Assets falls into.



Biotage AB Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Biotage AB's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )=Total Liabilities/Total Assets
=124.201/480.717
=0.26

Biotage AB's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 is calculated as

Liabilities-to-Assets (Q: Mar. 2024 )=Total Liabilities/Total Assets
=120.83/494.367
=0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biotage AB  (OTCPK:BITGF) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Biotage AB Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Biotage AB's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotage AB (Biotage AB) Business Description

Traded in Other Exchanges
Address
Vimpelgatan 5, Box 8, Uppsala, SWE, 751 03
Biotage AB provides separation technology and solutions for analytical and organic chemistry from research to commercial analytical laboratories and industrial applications. Its customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research, and contract manufacturers as well as clinical, forensic, and academic laboratories in addition to organizations focused on food safety, clean water, and environmental sustainability. It serves three geographic markets: The Americas, APAC (Asia-Pacific,) and EMEA (Europe, Middle East & Africa). The company's product areas include Small Molecules & Synthetic Therapeutics, Biologics & Advanced Therapeutics, Scale-Up, Diagnostics, Analytical Testing, and Water & Environmental Testing.

Biotage AB (Biotage AB) Headlines

From GuruFocus

Biotage AB (publ) Interim report January - September 2021

By PRNewswire PRNewswire 10-28-2021

Biotage AB (publ) appoints new CFO

By PRNewswire PRNewswire 07-01-2021

Biotage AB (publ) Interim Report January - March 2020

By PRNewswire PRNewswire 04-28-2020

Biotage AB (publ) Interim report January - March 2021

By PRNewswire PRNewswire 04-28-2021

Biotage - change in number of shares and votes

By PRNewswire PRNewswire 08-31-2020

Notice of Annual General Meeting in Biotage AB (publ)

By PRNewswire PRNewswire 04-28-2020